Everything below concerns peptide mapping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-18. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
== Applications == Estimation of the size of DNA molecules following restriction enzyme digestion, e.g. in restriction mapping of cloned DNA. Analysis of PCR products, e.g. in molecular genetic diagnosis or genetic fingerprinting Separation of restricted genomic DNA prior to Southern transfer, or of RNA prior to Northern transfer. Gel electrophoresis is used in forensics, molecular biology, genetics, microbiology and biochemistry. The results can be analyzed quantitatively by visualizing the gel with UV light and a gel imaging device. The image is recorded with a computer-operated camera, and the intensity of the band or spot of interest is measured and compared against standard or markers loaded on the same gel. The measurement and analysis are mostly done with specialized software. Depending on the type of analysis being performed, other techniques are often implemented in conjunction with the results of gel electrophoresis, providing a wide range of field-specific applications.
== Polymerization == Polypropylene glycol is produced by ring-opening polymerization of propylene oxide. The initiator is an alcohol and the catalyst a base, usually potassium hydroxide. When the initiator is ethylene glycol or water the polymer is linear. With a multifunctional initiator like glycerine, pentaerythritol or sorbitol the polymer branches out.
== Targeted protein degradation == In 2001, work from the labs of Craig Crews and Raymond Deshaies described the development of proteolysis-targeting chimeras (PROTACs). Using a small molecule to recruit an E3 ubiquitin ligase to a target protein, this work demonstrated that induced proximity could be used to effect the ubiquitination and proteasomal degradation of a target protein. PROTACs have been frequently applied using the E3 ubiquitin ligases CRBN and VHL to degrade various targets of biological and therapeutic relevance. Multiple groups have sought out additional E3 ligases to co-opt for targeted protein degradation such as FBXO22 and KLHDC2. While PROTACs generally are heterobifunctional compounds linking an E3 ligase binder to a target protein binder, molecular glues also exist that induce protein-protein interactions with E3 ligases, leading to degradation of various substrate proteins. Molecular glues often have been discovered through serendipity, though various methodologies have been explored to expedite the discovery of molecular glues. Biologic modalities for targeted protein degradation have also been explored by fusing E3 ligases to target recognition domains such as nanobodies. These modalities are sometimes referred to as bioPROTACs. While bioPROTACs are advantageous for targeting proteins lacking small molecule ligands, challenges in delivery, pharmacokinetics, and immunogenicity have so far precluded clinical development. Studies exploring different delivery mechanisms have sought to address these shortcomings.
Sources: en.wikipedia.org
Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
=== EC 1.7.99 With other acceptors === EC 1.7.99.1: hydroxylamine reductase EC 1.7.99.2: deleted: reaction may have been due to the combined action of EC 1.7.99.6 nitrous-oxide reductase and EC 1.7.99.7 nitric-oxide reductase EC 1.7.99.3: Now included with EC 1.7.2.1, nitrite reductase (NO-forming) EC 1.7.99.4: Now EC 1.7.1.1, nitrate reductase (NADH), EC 1.7.1.2, nitrate reductase [NAD(P)H], EC 1.7.1.3, nitrate reductase (NADPH), EC 1.7.5.1, nitrate reductase (quinone), EC 1.7.7.2, nitrate reductase (ferredoxin) and EC 1.9.6.1, nitrate reductase (cytochrome) EC 1.7.99.5: Now included with EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.7.99.6: Now EC 1.7.2.4 nitrous-oxide reductase EC 1.7.99.7: Now EC 1.7.2.5 nitric oxide reductase (cytochrome c) EC 1.7.99.8: hydroxylamine oxidoreductase EC 1.7.99.8: Now classified as EC 1.7.2.8, hydrazine dehydrogenase
==== Combination of fields ==== The most effective self-assembly director is a combination of external force fields. If the fields and conditions are optimized, self-assembly can be permanent and complete. When a field combination is used with nanoparticles that are tailored to be intrinsically responsive, the most complete assembly is observed. Combinations of fields allow the benefits of self-assembly, such as scalability and simplicity, to be maintained while being able to control orientation and structure formation. Field combinations possess the greatest potential for future directed self-assembly work.
Sources: en.wikipedia.org
The International Union of Pure and Applied Chemistry (IUPAC) initially established lawrencium as the official name for the element and gave the American team credit for the discovery; this was reevaluated in 1992, giving both teams shared credit for the discovery but not changing the element's name.
U+039B Λ GREEK CAPITAL LETTER LAMDA (Λ) U+03BB λ GREEK SMALL LETTER LAMDA (λ) U+1D27 ᴧ GREEK LETTER SMALL CAPITAL LAMDA U+2C96 Ⲗ COPTIC CAPITAL LETTER LAULA U+2C97 ⲗ COPTIC SMALL LETTER LAULA U+A7DA LATIN CAPITAL LETTER LAMBDA U+A7DB LATIN SMALL LETTER LAMBDA U+1038D 𐎍 UGARITIC LETTER LAMDA U+1D6B2 𝚲 MATHEMATICAL BOLD CAPITAL LAMDA U+1D6CC 𝛌 MATHEMATICAL BOLD SMALL LAMDA U+1D6EC 𝛬 MATHEMATICAL ITALIC CAPITAL LAMDA U+1D706 𝜆 MATHEMATICAL ITALIC SMALL LAMDA U+1D726 𝜦 MATHEMATICAL BOLD ITALIC CAPITAL LAMDA U+1D740 𝝀 MATHEMATICAL BOLD ITALIC SMALL LAMDA U+1D760 𝝠 MATHEMATICAL SANS-SERIF BOLD CAPITAL LAMDA U+1D77A 𝝺 MATHEMATICAL SANS-SERIF BOLD SMALL LAMDA U+1D79A 𝞚 MATHEMATICAL SANS-SERIF BOLD ITALIC CAPITAL LAMDA U+1D7B4 𝞴 MATHEMATICAL SANS-SERIF BOLD ITALIC SMALL LAMDA
The term "Fearsome Foursome" as applied in professional football in the United States has been used as a nickname for the defensive lines of the New York Giants and Baltimore Colts of the late 1950s in the National Football League (NFL), the San Diego Chargers of the early 1960s in the American Football League (AFL), the Detroit Lions of the early to mid-1960s, and various Los Angeles Rams' defensive lines of the 1960s and 1970s in the NFL. The term has also been used more generically to describe a top team's high performing defensive line. In a 1972 Boston Globe article, a chart of "Famous 'Fearsome Foursomes'" was included that compared the Chargers and Rams who had the Fearsome Foursome nickname, but also included, the 1968 era Green Bay Packers' line, and the defensive lines of the Dallas Cowboys (the "Doomsday Defense"), Minnesota Vikings ("Purple People Eaters"), Kansas City Chiefs and San Francisco 49ers of the 1970s. Sportswriter John Crittenden said in 1975 there had been a dozen defensive lines known as fearsome foursomes.
== Uses == Benzene is used mainly as an intermediate to make other chemicals, above all ethylbenzene (and other alkylbenzenes), cumene, cyclohexane, and nitrobenzene. In 1988, it was reported that two-thirds of all chemicals on the American Chemical Society's lists contained at least one benzene ring. More than half of the entire benzene production is processed into ethylbenzene, a precursor to styrene, which is used to make polymers and plastics like polystyrene. Some 20% of the benzene production is used to manufacture cumene, which is needed to produce phenol and acetone for resins and adhesives. Cyclohexane consumes around 10% of the world's benzene production; it is primarily used in the manufacture of nylon fibers, which are processed into textiles and engineering plastics. Smaller amounts of benzene are used to make some types of rubbers, lubricants, dyes, detergents, drugs, explosives, and pesticides. In 2013, the biggest consumer country of benzene was China, followed by the USA. Benzene production is currently expanding in the Middle East and in Africa, whereas production capacities in Western Europe and North America are stagnating. Toluene is now often used as a substitute for benzene, for instance as a fuel additive. The solvent-properties of the two are similar, but toluene is less toxic and has a wider liquid range. Toluene is also processed into benzene.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.